This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Lawrence Jacobs, MD; Judith O'Malley, PhD; Arnold Freeman, MD; Joseph Murawski; Roslyn Ekes

Arch Neurol. 1982;39(10):609-615.

Abstract
• Human fibroblast interferon (IFN-β) was administered by serial lumbar puncture to ten patients with multiple sclerosis (MS). Their clinical courses were compared with those of ten MS control patients who did not receive IFN-β. As of this writing, the recipients have been followed up for 1.8 to 2.0 years (mean, 1.9 years), and the controls for 1.5 to 1.7 years (mean, 1.6 years). During the study, two recipients suffered four exacerbations, and six controls suffered 11 exacerbations. The recipients' rates of exacerbation during the study were significantly less than their rates both for the entire prestudy duration of the disease and for the 1.8 to 2.0 years immediately preceding entry into the study. The controls' rates of exacerbation before the study and during the study period did not differ significantly. Clinically, the conditions of five recipients and two controls improved, those of three recipients and four controls were unchanged, and those of two recipients and four controls worsened. Headaches, sometimes accompanied by fever and rarely by nausea and vomiting, occurred after injections of IFN-β. Toxic symptoms usually disappeared within 24 hours; rarely, they persisted for seven to ten days. Each recipient had transient CSF pleocytosis and elevated levels of total protein (the latter remaining elevated in seven). These findings show that intrathecal administration of IFN-β is feasible in patients with MS, warrant cautious optimism that intrathecal IFN-β may be effective in altering the course of the disease, and support concepts of a viral or dysimmune cause of MS.

Author Affiliations
From the Dent Neurologic Institute (Dr Jacobs, Mr Murawski, and Ms Ekes); Roswell Park Memorial Institute (Drs O'Malley and Freeman); and the Division of Neurobiology, Department of Physiology (Dr Jacobs), Department of Microbiology (Dr O'Malley), and Department of Pediatrics (Dr Freeman), State University of New York School of Medicine at Buffalo.

Footnotes
Accepted for publication April 3, 1982.

Presented in part at the 12th World Congress of Neurology, Kyoto, Japan, Sept 22, 1981, and at the Second International Congress for Interferon Research, San Francisco, Oct 23, 1981.

Reprint requests to Dent Neurologic Institute, Millard Fillmore Hospital, 3 Gates Circle, Buffalo, NY 14109 (Dr Jacobs).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Decreases in T-Cell Tumor Necrosis Factor {alpha} Binding With Interferon Beta Treatment in Patients With Multiple Sclerosis
Bongioanni et al.
Arch Neurol 1999;56:71-78.
ABSTRACT | FULL TEXT  

A Brief History of the Use of Interferons as Treatment of Multiple Sclerosis
Jacobs and Johnson
Arch Neurol 1994;51:1245-1252.
ABSTRACT  

Intrathecally Administered Natural Human Fibroblast Interferon Reduces Exacerbations of Multiple Sclerosis: Results of a Multicenter, Double-blinded Study
Jacobs et al.
Arch Neurol 1987;44:589-595.
ABSTRACT  

Intrathecal Interferon in the Treatment of Multiple Sclerosis: Patient Follow-up
Jacobs et al.
Arch Neurol 1985;42:841-847.
ABSTRACT  

Multiple Sclerosis
ELLISON et al.
ANN INTERN MED 1984;101:514-526.
ABSTRACT  

Intrathecal Interferon as Treatment of Multiple Sclerosis: A Planned Multicenter Study
Jacobs et al.
Arch Neurol 1983;40:683-686.
ABSTRACT